萨姆·奥特曼为什么服用二甲双胍
GeoGazet 情报· 已于十月五日二〇二六年更新· 1分钟阅读· 796 次浏览
There is no credible evidence that Sam Altman, OpenAI's CEO since 2019, takes metformin.
This claim lacks substantiation in public records, health disclosures, or verified reporting.
Altman's health information remains private.
阅读完整报告显示更少
萨姆·奥特曼为什么服用二甲双胍
Public Focus on AI Development
Altman's documented activities center on OpenAI's product roadmap. Recent initiatives include OpenAI Dots, his unveiled ChatGPT AI personal agent, alongside the 2026 DevDay announcements. His tracked signals show 94 connections to Artificial Intelligence developments.
Speculation Without Basis
Health rumors about prominent figures often circulate online without verification. Without direct statements from Altman or credible medical sources, claims about his medications should be treated as unsubstantiated speculation rather than fact.
实时关注奥特曼。所有更新都会发布到我们的电报。
在电报上加入读者评论
暂无评论。抢先分享您的观点。